Navigation Links
Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
Date:6/22/2011

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study.  The propriety formulation was designed and manufactured at Particle Sciences.  In the Phase 1 clinical trial NRL-1 demonstrated a pharmacokinetic profile comparable to that reported in the literature for Diastat® (rectal diazepam gel), the only FDA approved therapeutic product for home treatment of acute repetitive seizures.  The bioavailability of the NRL-1 intranasal formulation was 96%.

According to Dr. Robert Lee, Particle Sciences VP of Pharmaceutical Development, "We are obviously very pleased with the results Neurelis have obtained.  It has been a pleasure working with them and very rewarding to contribute to a product that should truly improve the quality of life for patients with acute repetitive seizures and their caregivers.  We were able to achieve extremely high levels of solubilized diazepam using our DOSE® platform that combines empirically obtained data with customized solubility software.  This approach along with Particle Sciences' cGMP analytical and manufacturing services have enabled our clients to more rapidly advance to the clinic with commercially viable formulations."

David F. Hale, Chairman of Neurelis, said that "The team at Neurelis was very pleased with the work on the formulation conducted by Particle Sciences.  They really focused on a key issue with diazepam which is solubility and developed two proprietary formulations which we evaluated in the clinical trial.  Based on the results obtained in the clinical trial we plan to move ahead with the further development of this product candidate for patients with epilepsy who have acute repetitive seizures."

Particle Sciences Inc. is an integrated provider of drug development services.  Particle Sciences utilizes a broad suite of drug delivery technologies to address a diverse range of challenges.  With special expertise in solubility, particulate based formulations and drug/device combination products, Particle Sciences has become a leader in drug delivery development.  Through a full range of formulation, analytic, bioanalytic, and sterile and non-sterile manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: Maureen Cochran
mcochran@particlesciences.com
610-861-4701


'/>"/>
SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
5. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
6. Particle Sciences Expands Its Combination Product Capabilities
7. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
8. Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities
9. MicroConstants Now Offers Nanoparticle Formulation Services
10. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
11. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 24, 2017 Mezzion has filed a ... State court alleging that Dr. Reddy,s committed fraud relating ... and Drug Administration (FDA) cGMP practices, and misrepresenting its ... repeatedly represented to Mezzion that it was compliant with ... Mezzion.  The suit also states that Dr. Reddy,s misconduct ...
(Date:1/24/2017)... , Jan 24, 2017 Research and Markets ... Trends - Sensor, Actuator - Forecast to 2025" report to ... ... around 17.6% over the next decade to reach approximately $76.24 million ... market is witnessing include growing count of labs using optogentic techniques ...
(Date:1/24/2017)... Stock-Callers.com today has issued research reports ... ZTS ), Mallinckrodt PLC (NYSE: MNK ), Akorn ... (NYSE: DPLO ). According to pharmaceutical manufacturer PCI ... for the Generic Drugs industry, including a possible reduction in ... growth, and a speedier FDA approval process that could reduce ...
Breaking Medicine Technology:
(Date:1/24/2017)... Santa Rosa, CA (PRWEB) , ... January 24, 2017 , ... ... rates is good news for everyone and particularly good news for prostate cancer patients: ... from the diagnosis. , According to the report the cancer death rate has dropped ...
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... for everyday use to improve the connection with God. “Spiritual Vitamins: A Spiritual ... author. , Published by Christian Faith Publishing, Mathai Yohannan’s new book engages the ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink ... , CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who ...
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home ... acquisitions of two personal care service companies: Padre Home Health in Corpus Christi, ... 1, 2017. , Well regarded in their respective markets, these two agencies align ...
Breaking Medicine News(10 mins):